Odyssey Therapeutics (Nasdaq: ODTX) reports $91.1M loss, $433.1M cash
Odyssey Therapeutics (ODTX) reported a net loss of $91.1 million for the first half of 2026, an increase from $79.7 million in the same period last year, primarily due to continued investment in its pipeline and higher non-cash contingent consideration expense. Following a May …